CHADD urges FDA to move forward with ADHD study of drug risks.(Children and Adults with Attention-Deficit Hyperactivity Disorder)(Food and Drug Administration)(Attention-Deficit Hyperactivity Disorder)

Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) earlier this month raised concerns about a recent Los Angeles Times article, which indicated that the Food and Drug Administration (FDA) may halt an ADHD safety study due to budget constraints.

The Los Angeles Times article, "FDA Budget Malnourished: A study of ADHD drug risks may be halted as the agency struggles to keep up with demands" (October 7, 2006), indicated that scientific advisors in February had urged FDA to put a strong warning about suspected cardiovascular risks on attention-deficit drugs (see MHW, March 20). Agency officials responded that more clinical evidence was needed, the …